Helus Pharma Inc. (HELP)

$7.73 -1.24 (-13.82%)
Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 864,772
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts N/A
Price Target N/A

Company Profile

Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterate...

Industry: Biotechnology
Sector: Healthcare
Phone: 908-764-8385
Website: cybin.com
Address:
100 King Street West, Suite 5600, Toronto, Canada
HelusPharmaIR
HelusPharmaIR Mar. 20 at 9:27 PM
$HELP Thank you for your comment! That shorter treatment window is an important part of the approach. In the study, acute effects lasted about 90 minutes, and patients were typically ready for discharge within a few hours. That kind of timeframe could make a real difference when thinking about how treatments fit into clinical practice.
1 · Reply
HelusPharmaIR
HelusPharmaIR Mar. 20 at 9:21 PM
$HELP With more than 20 years of leadership in biotechnology and pharmaceuticals, Jill Conwell brings extensive experience helping organizations evolve as their strategies and pipelines mature. Her career includes senior leadership roles at Aclaris Therapeutics, Idera Pharmaceuticals, and Shire Pharmaceuticals, where she partnered closely with executive teams and boards during periods of clinical advancement and corporate transformation. In addition to leading human resources functions, Jill has worked across corporate communications and investor relations, bringing a broader strategic perspective to companies navigating complex growth phases. We welcome her and the perspective she will bring to the team.
1 · Reply
BobJohnBuoy666
BobJohnBuoy666 Mar. 20 at 3:52 PM
$HELP they are signaling to be bought out. The acquisition angle has always been my reason for investing here. Brand update, large cash position, new CEO, ex-Pfizer exec on board, suspicious drop on decent data (similar to CMPS last year), some evidence of dark pool accumulation, suspiciously low volume despite normal float size suggesting that large holders are just holding and not actively trading. Obviously completely different situations but I am reminded of $DRUG from a few years ago. Could happen, might now, I am positioned extremely aggressively for if it does.
0 · Reply
Where_is_my_lambo
Where_is_my_lambo Mar. 19 at 11:10 PM
$HELP hopefully Jill will fire you for your embarrassing continued use of AI to communicate to shareholders and investors, and suggest to Michael Cola that he should have a Q&A with investors and shareholders to address the 40% stock price crash last week following the obvious disconnect of expectations vs announced results for 004, and his boring reading of the data during his presentation.
0 · Reply
HelusPharmaIR
HelusPharmaIR Mar. 19 at 8:32 PM
$HELP Last week we welcomed Jill Conwell to Helus Pharma as Chief People Officer, strengthening our executive leadership team as the company continues to evolve. Jill brings more than two decades of experience across the life sciences sector, where she has helped organizations scale their teams, align talent with business strategy, and support companies navigating periods of growth and transformation. Her leadership experience spans human resources, corporate communications, and investor relations. As Helus continues advancing its neuroscience pipeline, building the right internal structure remains a priority. Jill’s experience in organizational development will help support the next phase of growth as the company continues progressing its clinical programs.
1 · Reply
firetypecracker
firetypecracker Mar. 18 at 8:18 PM
$HELP Cybin(Helus Pharma) : Corporate Presentation March 2026 Cybin outlined two proprietary clinical programs, HLP003 and HLP004, targeting major depressive disorder and generalized anxiety disorder, and reported positive Phase 2 safety and efficacy results. The company said HLP003 has received FDA Breakthrough Therapy Designation and is in Phase 3 studies for adjunctive treatment of major depressive disorder. Cybin expects topline data from the Phase 3 APPROACH study in Q4 2026. The presentation said Cybin has filed more than 350 patents, with more than 100 granted, and cited patent protection through at least 2041. https://www.marketscreener.com/news/cybin-corporate-presentation-march-2026-ce7e5ed9da8df024
1 · Reply
StockDudeManCan
StockDudeManCan Mar. 18 at 6:38 PM
$HELP I guess the upside of going down so much in such a short amount of time is on overall market down days. The stock is holding up.
0 · Reply
navle
navle Mar. 18 at 5:51 PM
$CMPS $ATAI $DFTX $HELP In the field of psychedelic medicine, I don't think they're worried about the competition coming from $IXHL
1 · Reply
Apes_Strong
Apes_Strong Mar. 18 at 3:26 PM
$ATAI $CMPS $DFTX $HELP anything else from the commentary ? Or Q and a ?
1 · Reply
Hindsight1989
Hindsight1989 Mar. 18 at 3:02 PM
$CMPS $ATAI $DFTX $HELP Kabir Nath, CEO of CMPS today: "we are heads down, focused on executing. We are focused on the competition at launch, which is Spravato. Yeah, we're not focused on the theoretical, yet to be proven, vague, and not very tolerable competition that might be coming behind." Strong words from CMPS. Market hasn't been buying what CMPS is selling, but I think the market is getting it wrong. I still believe CMPS is the most undervalued relative to the risks and opportunity, and will significantly re-rate in the next 9-12 months.
1 · Reply
Latest News on HELP
Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer

Mar 12, 2026, 7:30 AM EDT - 9 days ago

Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer

Cybin Inc. (HELP) Discusses Phase II Results for HLP004 in Generalized Anxiety Disorder Prepared Remarks Transcript

Mar 6, 2026, 10:15 AM EST - 15 days ago

Cybin Inc. (HELP) Discusses Phase II Results for HLP004 in Generalized Anxiety Disorder Prepared Remarks Transcript

Helus Pharma Stock Tumbles As Anxiety Drug Study Disappoints

Mar 5, 2026, 10:38 AM EST - 16 days ago

Helus Pharma Stock Tumbles As Anxiety Drug Study Disappoints

Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder

Mar 5, 2026, 7:30 AM EST - 16 days ago

Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder

HELUS Pharma: Transitioning From Psychedelic Research To Late-Stage Clinical Neuroscience

Feb 24, 2026, 11:55 PM EST - 24 days ago

HELUS Pharma: Transitioning From Psychedelic Research To Late-Stage Clinical Neuroscience

Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee

Feb 24, 2026, 7:45 AM EST - 25 days ago

Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee

Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder

Feb 17, 2026, 7:30 AM EST - 4 weeks ago

Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder

HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

Feb 13, 2026, 7:31 AM EST - 5 weeks ago

HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

Cybin Initiates At-The-Market Equity Program of up to US$100 Million

Dec 30, 2025, 3:33 PM EST - 2 months ago

Cybin Initiates At-The-Market Equity Program of up to US$100 Million

Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq

Dec 18, 2025, 12:29 PM EST - 3 months ago

Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq

Cybin Inc. (CYBN) Q2 2026 Earnings Call Transcript

Nov 13, 2025, 3:11 PM EST - 4 months ago

Cybin Inc. (CYBN) Q2 2026 Earnings Call Transcript

Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

Nov 13, 2025, 7:20 AM EST - 4 months ago

Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

Cybin to Participate in the Jefferies Global Healthcare Conference in London

Nov 12, 2025, 7:30 AM EST - 4 months ago

Cybin to Participate in the Jefferies Global Healthcare Conference in London

Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025

Nov 6, 2025, 7:30 AM EST - 4 months ago

Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025

Cybin to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Nov 5, 2025, 7:30 AM EST - 4 months ago

Cybin to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Cybin to Participate at the 2025 Milken Institute Future of Health Summit

Nov 3, 2025, 7:30 AM EST - 4 months ago

Cybin to Participate at the 2025 Milken Institute Future of Health Summit

Cybin Announces Closing of $175 Million Registered Direct Offering

Oct 31, 2025, 4:19 PM EDT - 5 months ago

Cybin Announces Closing of $175 Million Registered Direct Offering

Cybin Announces $175 Million Registered Direct Offering

Oct 28, 2025, 8:00 AM EDT - 5 months ago

Cybin Announces $175 Million Registered Direct Offering

BetterLife Pharma Appoints Doug Drysdale as Corporate Advisor

Oct 21, 2025, 8:00 AM EDT - 5 months ago

BetterLife Pharma Appoints Doug Drysdale as Corporate Advisor

Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones

Sep 23, 2025, 5:00 PM EDT - 6 months ago

Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones

CYBN Investors Have Opportunity to Join Cybin Inc. Fraud Investigation with the Schall Law Firm

Sep 11, 2025, 3:59 PM EDT - 6 months ago

CYBN Investors Have Opportunity to Join Cybin Inc. Fraud Investigation with the Schall Law Firm

Cybin to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Sep 11, 2025, 7:30 AM EDT - 6 months ago

Cybin to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder

Sep 8, 2025, 7:30 AM EDT - 6 months ago

Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder

Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 7:30 AM EDT - 7 months ago

Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Cybin to Participate in the Cantor Global Healthcare Conference 2025

Sep 3, 2025, 7:30 AM EDT - 7 months ago

Cybin to Participate in the Cantor Global Healthcare Conference 2025

Cybin Announces Senior Leadership Changes

Sep 2, 2025, 7:30 AM EDT - 7 months ago

Cybin Announces Senior Leadership Changes

Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Aug 26, 2025, 7:30 AM EDT - 7 months ago

Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Cybin Announces Results of Annual Meeting of Shareholders

Aug 18, 2025, 5:30 PM EDT - 7 months ago

Cybin Announces Results of Annual Meeting of Shareholders

Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results

Aug 13, 2025, 5:30 PM EDT - 7 months ago

Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results

Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Aug 7, 2025, 7:30 AM EDT - 8 months ago

Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference

Aug 6, 2025, 7:30 AM EDT - 8 months ago

Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference

Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Jul 17, 2025, 7:30 AM EDT - 8 months ago

Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Jul 1, 2025, 11:19 AM EDT - 9 months ago

REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights

Jun 30, 2025, 10:03 PM EDT - 9 months ago

Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights

Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Jun 30, 2025, 9:27 PM EDT - 9 months ago

Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics

Jun 13, 2025, 7:45 AM EDT - 10 months ago

Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics

Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference

Jun 12, 2025, 7:30 AM EDT - 10 months ago

Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference

Cybin to Participate in the 2025 Psychedelic Science Conference

Jun 11, 2025, 7:30 AM EDT - 10 months ago

Cybin to Participate in the 2025 Psychedelic Science Conference

Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder

Jun 3, 2025, 7:30 AM EDT - 10 months ago

Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder

Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025

May 22, 2025, 7:30 AM EDT - 10 months ago

Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025

Cybin Applauds FDA Commissioner Dr. Martin Makary's Call to Accelerate and Prioritize Research on Psychedelic Therapeutics

May 20, 2025, 7:30 AM EDT - 10 months ago

Cybin Applauds FDA Commissioner Dr. Martin Makary's Call to Accelerate and Prioritize Research on Psychedelic Therapeutics

Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder

May 15, 2025, 7:30 AM EDT - 11 months ago

Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder

Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase

May 14, 2025, 7:30 AM EDT - 11 months ago

Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase

Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder

May 8, 2025, 7:30 AM EDT - 11 months ago

Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder

Cybin to Participate at the 28th Annual Milken Institute Global Conference

May 1, 2025, 7:30 AM EDT - 11 months ago

Cybin to Participate at the 28th Annual Milken Institute Global Conference

Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003

Apr 23, 2025, 7:30 AM EDT - 11 months ago

Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003

Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs

Apr 21, 2025, 8:00 AM EDT - 11 months ago

Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs

HelusPharmaIR
HelusPharmaIR Mar. 20 at 9:27 PM
$HELP Thank you for your comment! That shorter treatment window is an important part of the approach. In the study, acute effects lasted about 90 minutes, and patients were typically ready for discharge within a few hours. That kind of timeframe could make a real difference when thinking about how treatments fit into clinical practice.
1 · Reply
HelusPharmaIR
HelusPharmaIR Mar. 20 at 9:21 PM
$HELP With more than 20 years of leadership in biotechnology and pharmaceuticals, Jill Conwell brings extensive experience helping organizations evolve as their strategies and pipelines mature. Her career includes senior leadership roles at Aclaris Therapeutics, Idera Pharmaceuticals, and Shire Pharmaceuticals, where she partnered closely with executive teams and boards during periods of clinical advancement and corporate transformation. In addition to leading human resources functions, Jill has worked across corporate communications and investor relations, bringing a broader strategic perspective to companies navigating complex growth phases. We welcome her and the perspective she will bring to the team.
1 · Reply
BobJohnBuoy666
BobJohnBuoy666 Mar. 20 at 3:52 PM
$HELP they are signaling to be bought out. The acquisition angle has always been my reason for investing here. Brand update, large cash position, new CEO, ex-Pfizer exec on board, suspicious drop on decent data (similar to CMPS last year), some evidence of dark pool accumulation, suspiciously low volume despite normal float size suggesting that large holders are just holding and not actively trading. Obviously completely different situations but I am reminded of $DRUG from a few years ago. Could happen, might now, I am positioned extremely aggressively for if it does.
0 · Reply
Where_is_my_lambo
Where_is_my_lambo Mar. 19 at 11:10 PM
$HELP hopefully Jill will fire you for your embarrassing continued use of AI to communicate to shareholders and investors, and suggest to Michael Cola that he should have a Q&A with investors and shareholders to address the 40% stock price crash last week following the obvious disconnect of expectations vs announced results for 004, and his boring reading of the data during his presentation.
0 · Reply
HelusPharmaIR
HelusPharmaIR Mar. 19 at 8:32 PM
$HELP Last week we welcomed Jill Conwell to Helus Pharma as Chief People Officer, strengthening our executive leadership team as the company continues to evolve. Jill brings more than two decades of experience across the life sciences sector, where she has helped organizations scale their teams, align talent with business strategy, and support companies navigating periods of growth and transformation. Her leadership experience spans human resources, corporate communications, and investor relations. As Helus continues advancing its neuroscience pipeline, building the right internal structure remains a priority. Jill’s experience in organizational development will help support the next phase of growth as the company continues progressing its clinical programs.
1 · Reply
firetypecracker
firetypecracker Mar. 18 at 8:18 PM
$HELP Cybin(Helus Pharma) : Corporate Presentation March 2026 Cybin outlined two proprietary clinical programs, HLP003 and HLP004, targeting major depressive disorder and generalized anxiety disorder, and reported positive Phase 2 safety and efficacy results. The company said HLP003 has received FDA Breakthrough Therapy Designation and is in Phase 3 studies for adjunctive treatment of major depressive disorder. Cybin expects topline data from the Phase 3 APPROACH study in Q4 2026. The presentation said Cybin has filed more than 350 patents, with more than 100 granted, and cited patent protection through at least 2041. https://www.marketscreener.com/news/cybin-corporate-presentation-march-2026-ce7e5ed9da8df024
1 · Reply
StockDudeManCan
StockDudeManCan Mar. 18 at 6:38 PM
$HELP I guess the upside of going down so much in such a short amount of time is on overall market down days. The stock is holding up.
0 · Reply
navle
navle Mar. 18 at 5:51 PM
$CMPS $ATAI $DFTX $HELP In the field of psychedelic medicine, I don't think they're worried about the competition coming from $IXHL
1 · Reply
Apes_Strong
Apes_Strong Mar. 18 at 3:26 PM
$ATAI $CMPS $DFTX $HELP anything else from the commentary ? Or Q and a ?
1 · Reply
Hindsight1989
Hindsight1989 Mar. 18 at 3:02 PM
$CMPS $ATAI $DFTX $HELP Kabir Nath, CEO of CMPS today: "we are heads down, focused on executing. We are focused on the competition at launch, which is Spravato. Yeah, we're not focused on the theoretical, yet to be proven, vague, and not very tolerable competition that might be coming behind." Strong words from CMPS. Market hasn't been buying what CMPS is selling, but I think the market is getting it wrong. I still believe CMPS is the most undervalued relative to the risks and opportunity, and will significantly re-rate in the next 9-12 months.
1 · Reply
BobJohnBuoy666
BobJohnBuoy666 Mar. 18 at 1:08 PM
$HELP interesting…
1 · Reply
Framingtheworld
Framingtheworld Mar. 18 at 1:59 AM
$HELP this thing is gonna rip! Strengthening the management is the main reason this went down. Easy 4x catch up play to $ATAI $DFTX $CMPS
1 · Reply
Not_Rico_Again_Jorge
Not_Rico_Again_Jorge Mar. 17 at 10:44 PM
$HELP Idiots gonna do idiot things
2 · Reply
StockDudeManCan
StockDudeManCan Mar. 17 at 8:50 PM
$HELP is this the move back or a head fake
0 · Reply
BobJohnBuoy666
BobJohnBuoy666 Mar. 17 at 8:17 PM
$HELP attached is weekly view of HELP and IBRX. Expecting same sort of resolution. NOT ADVICE, I could be a major dumb dumb
0 · Reply
BobJohnBuoy666
BobJohnBuoy666 Mar. 17 at 8:14 PM
$HELP ok, finally have enough information from the gap down day. Based on how the order flows and price movements have been, I expect an angry move aimed at 5.50; whether or not it successfully plants a sustainable rally will be the real test…but the pattern seems to imply they want retail scared out of their positions : bleed it lower on volume, gap it up on low volume. I still think dark pools are accumulating.
1 · Reply
StockDudeManCan
StockDudeManCan Mar. 17 at 8:01 PM
$HELP 2 up days in a row!!! Holy crap
1 · Reply
HughJasol
HughJasol Mar. 17 at 4:56 PM
$HELP oh I know there are new people suddenly looking at this like a great buying opportunity…. Don’t buy this stock. It will take all your investment
1 · Reply
Citychickens
Citychickens Mar. 17 at 3:41 PM
$HELP is about to rally as my options expire Friday, they don't like when I make any coin so almost a guarantee we get a price jump!!!
1 · Reply
Bbbb44444
Bbbb44444 Mar. 17 at 2:31 PM
$HELP When next dilution?
1 · Reply
StockDudeManCan
StockDudeManCan Mar. 16 at 8:01 PM
$HELP oh Shi! An up day
0 · Reply
StockDudeManCan
StockDudeManCan Mar. 16 at 7:47 PM
$HELP everyday from 330-4pm this thing gets whacked. Wtf
0 · Reply